Key result
Thrombolysis for acute PE requires clinical, biomarker, and imaging stratification to optimize patient benefit.
Why the study?
Identifying patients at highest risk of death from acute pulmonary embolism is critical to select those who would benefit most from thrombolytic therapy.
Population
Patients with acute pulmonary embolism
Comparison
Thrombolytic therapy vs no thrombolytic therapy
Design
Review
Authors
Loading...
Supports risk stratification before thrombolysis in acute PE; leaves open optimal tool validation in prospective studies.
This review discusses the evolving role of thrombolytic therapy and risk stratification in the management of acute pulmonary embolism.
Vyas et al. (2012) conducted a review in Acute pulmonary embolism. Thrombolytic therapy was evaluated. Thrombolytic therapy for acute pulmonary embolism requires careful risk stratification using clinical prediction models, serum tests, and imaging to identify patients who would benefit most.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: